SS Innovations Reports Significant Financial Growth for Q2 2025
SS Innovations Q2 2025 Financial Highlights
Record Revenue of $10.0 Million with Substantial Growth in Surgical Robot Sales
SS Innovations International, Inc. (NASDAQ: SSII) disclosed its unaudited financial results for the second quarter of 2025, reflecting impressive growth driven by its advanced surgical technologies.
Notable Financial Achievements
Second Quarter Growth
- Revenue surged by 121.8%, reaching $10.0 million compared to $4.5 million in Q2 2024.
- Gross margin increased significantly to 59.1%, up from 31.9% in the prior year.
- Gross profit experienced a substantial rise of 311.4%, amounting to $5.9 million, compared to $1.4 million in Q2 2024.
- Net loss narrowed to $0.3 million, or $(0.00) per diluted share, significantly improved from a net loss of $4.1 million or $(0.02) per share in Q2 2024.
- The number of SSi Mantra surgical system installations reached 23, a 130% increase from 10 installations in Q2 2024.
First Half Highlights
- Total revenue for H1 2025 rose by 85.6% to $15.1 million, from $8.1 million in H1 2024.
- Gross profit for the first half was up 223.3%, totaling $7.0 million compared to $2.2 million a year earlier.
- Net loss for the first half shrank to $5.9 million from $14.0 million in 2024, showcasing improved financial discipline.
- SSi Mantra installations for the first half totaled 38, reflecting a 100% growth year-over-year.
Financial Position
As of June 30, 2025
- SS Innovations reported no long-term debt, emphasizing a strong balance sheet.
- The company maintains cash and cash equivalents totaling $11.4 million, excluding restricted cash.
- The cumulative installed base of the SSi Mantra robotic system grew to 105, encompassing seven countries with a total of 4,657 surgeries performed.
CEO Insights
Dr. Sudhir Srivastava, CEO of SS Innovations, stated, "We are thrilled to see our hard work resulting in significant revenue growth in Q2 2025. The higher sales of our cost-effective SSi Mantra 3 system, both domestically and internationally, reflect our commitment to making robotic surgery more accessible. The marked increase in gross profit and improved gross margins indicate our strategy is effectively reducing production costs and enhancing operational efficiency."
"Our SSi Mantra 3 system continues to break new ground, particularly in robotic telesurgery and cardiac applications, and we anticipate submitting a 510(k) application to the U.S. FDA for multiple indications by the close of Q3 2025, further accelerating our expansion opportunities. Our continuous engagement with regulatory bodies signals promising advancements towards securing a European CE mark by late 2025," he added.
Key Developments for Q2 2025
- In April 2025, SS Innovations achieved a significant milestone by listing its common stock on Nasdaq.
- The company celebrated its public market debut by ringing the opening bell at the Nasdaq MarketSite.
- Significantly, in June 2025, the SSi Mantra system performed its first robotic cardiac surgery in the Western Hemisphere.
Recent Milestones
- July 2025 marked the world's first robotic telesurgery for weight reduction completed with the SSi Mantra 3 system.
- The company also executed the first intercontinental robotic cardiac telesurgery.
- The SSi Mantra installations rose to a total of 112, with cumulative surgeries exceeding 5,038 since the system's introduction.
Strategic Outlook
Looking ahead, the expanding installed base of the SSi Mantra combined with growing operational efficiency positions SS Innovations favorably for sustained organic growth. With regulatory progress underway, the company is optimistic about unleashing further advancements in robotic surgical technology.
About SS Innovations
SS Innovations International, Inc. (NASDAQ: SSII) specializes in developing innovative surgical robotics aimed at democratizing access to advanced surgical procedures globally. Its flagship product, the SSi Mantra surgical system, alongside the SSi Mudra instruments, enables a wide array of surgical applications. Headquartered in India, the company is committed to broadening its footprint in the surgical robotics market.
Frequently Asked Questions
What is the recent revenue growth for SS Innovations?
The company reported a remarkable revenue increase of 121.8% in Q2 2025, climbing to $10.0 million.
How much did SS Innovations' gross profit increase?
Gross profit saw a 311.4% rise to $5.9 million compared to the same quarter last year.
What strategic developments have occurred for SS Innovations?
Recently, the company listed on Nasdaq and completed innovative robotic surgeries, setting new industry standards.
What are the future plans for SS Innovations regarding FDA submissions?
SS Innovations plans to submit a 510(k) application for the SSi Mantra 3 system by September 2025.
How many surgical systems has SS Innovations installed as of June 2025?
As of June 30, 2025, there were 105 SSi Mantra surgical systems installed worldwide.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
